Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 74,701 shares of the company's stock after buying an additional 4,123 shares during the quarter. Voya Investment Management LLC owned about 0.26% of Krystal Biotech worth $11,703,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. US Bancorp DE increased its stake in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after acquiring an additional 82 shares during the period. Summit Investment Advisors Inc. raised its stake in shares of Krystal Biotech by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after buying an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after buying an additional 121 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after buying an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in Krystal Biotech by 1.5% during the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after acquiring an additional 123 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KRYS has been the topic of several recent research reports. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. Finally, HC Wainwright upped their price target on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday, April 28th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $222.71.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Krystal Biotech Stock Performance

Shares of KRYS traded up $0.47 during trading hours on Friday, hitting $166.16. 228,173 shares of the stock were exchanged, compared to its average volume of 294,547. The stock's 50-day moving average price is $174.92 and its two-hundred day moving average price is $171.22. The company has a market cap of $4.80 billion, a price-to-earnings ratio of 55.57 and a beta of 0.79. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's revenue for the quarter was up 116.4% on a year-over-year basis. During the same period last year, the firm posted $0.30 earnings per share. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).